Results for the year ended 31 January 2017 Focusing and simplifying 3 May 2017
|
|
- Wesley Boone
- 5 years ago
- Views:
Transcription
1 Results for the year ended 31 January 2017 Focusing and simplifying
2 Business review Chris Rigg, Chief Executive Officer 1
3 Strategic progress Recent past Present Future New Board appointed Business simplification leading to balance sheet write-downs NuPharm closed in line with plan All trading losses across the Group eliminated Reported loss draws a line under past challenges Balance sheet recapitalised following 15.0m equity fundraise Lower net debt than expected at 13.0m Business well-placed and performing well Run-rate profitability increasing Specials division long-term contracts with AAH, Phoenix and Well Pharmacy secured Niche division transformed focused pipeline, successful launches and lower cost base All recently launched products performing as expected Products in development progressing to timetable, with a full pipeline Simplified strategy Focus on higher-margin Specials and Niche businesses Maximise UK opportunity to move up prescribing hierarchy Develop commercial and international partnerships Strategic review of Medication Adherence 2
4 Financial overview Revenue 88.8m 2016: 69.2m Gross profit 25.9m 2016: 25.9m Adjusted EBITDA 10.1m 2016: 12.5m Statutory operating loss (post-simplification) 9.8m 2016: 7.5m profit Net debt reduced by 11.6m to 13.0m 2016: 24.6m All figures for continuing operations 3
5 Our simplified business model & positioning Market position: No. 2 Licensed medicines preferred choice for patients and prescribers Specials prescribed if licensed medicine not available Specials market: 1% (c. 80m) of England and Wales 1 community prescription market Market backdrop characterised by tariff pricing and regulatory environment Market position: No. 1 1 As of
6 Our strategy Leverage existing business platform Focusing and simplifying Consolidate our market position Partnerships Specialist pharmaceutical business 5
7 Business updates 6
8 Portfolio update Carefully selected products for progression In development / licensing process 35 products Tighter focus allows management to devote more time and attention to the products that matter most MA received not launched 3 products Pipeline is full and includes 25 top UL2L opportunities Launched or out-licensed 19 products Selected larger niche generics with market opportunity will be commercialised in the near term Group has proven capability in developing and licensing products through Lamda Total 57 products Commercialising products through Colonis in the most effective way is key to realising their potential UL2L Non-UL2L Graph depicts number of individual UK-licensed products or developments that is post the impact of product discontinuation and cancelled developments. Branded and generic version of the Group s Vitamin D range (3 strengths across 6 product lines) are counted separately in the above analysis given their different routes to market. The above numbers do not include the range of Dermacool TM prescribable creams (4 products across 13 product lines) as they are not licensed products. A further 12 products are in feasibility assessment stage and are not part of the chart as they may not ultimately proceed to the development stage. 7
9 Launched portfolio update Portfolio EBITDA 1 excluding one-off items Niche division performing well Monthly profitability run-rate transformed Discontinuing underperforming products allowed for removal of supporting costs and greater focus on selected portfolio A number of products successfully launched in Q417 and post year-end are performing to plan, comprising: Break even Post year-end Acetylcysteine Sachets 200mg 3 Metformin Oral Solution strengths Folic Acid Oral Solution 5mg/5ml 3 Levothyroxine Oral Solution strengths Portfolio now consists of 19 UK-licensed products generating sustained revenue and margin, comprising 4 UK out-licenses and 15 launched products 1 Graph depicts EBITDA excluding out-licensing income (to neutralise lumpiness) and other non-recurring items such as restructuring costs. The depicted EBITDA includes the cost of supporting underperforming lines (to show the subsequent improvement following simplification), which is not included in adjusted EBITDA. 8
10 Sep-14 Oct-14 Nov-14 Dec-14 Jan-15 Feb-15 Mar-15 Apr-15 May-15 Jun-15 Jul-15 Aug-15 Sep-15 Oct-15 Nov-15 Dec-15 Jan-16 Feb-16 Mar-16 Apr-16 May-16 Jun-16 Jul-16 Aug-16 Sep-16 Specials 80,000 Prescribing of special order products on NHS prescriptions in England 1 vs QPL 2 order numbers in England (excluding special obtains) Despite market maturity and NHS budgetary pressure, Specials business has increased its market share Growth driven by core competencies and competitive advantages: 60,000 Service and quality Breadth of offering Contracted relationships 40,000 Recent long-term exclusive contracts entered into include: 20,000 AAH c.4 years remaining Well Pharmacy 2 years Phoenix Healthcare Distribution 3 years - Business experiencing some margin pressure resulting from switch to tariff lines Specials prescriptions QPL order numbers 1 NHS Business Services Authority website, updated to September Quantum Pharmaceutical Limited Hospital volumes serviced by UL Medicines growing Specials provides profitable, cash generative platform for licensing activities 9
11 Medication Adherence strategic review 2017 Medication Adherence Simplified Specials & Niche Revenue 88.8m ( 25.4m) 63.4m Gross profit 25.9m ( 1.9m) 24.0m Gross profit % 29.2% 7.5% 37.9% Adjusted EBITDA 10.1m 0.2m 10.3m Adjusted EBITDA % 11.4% n/a 16.2% Strategy is to focus on the two core pillars of Specials and Niche A more focused core business means: Lower revenue Higher gross and adjusted EBITDA margin Higher quality earnings Opportunity for further efficiencies 10
12 Financial review Gerard Murray, Chief Financial Officer 11
13 Financial summary Continuing operations Revenue 88.8m 69.2m Gross profit 25.9m 25.9m Gross profit % 29.2% 37.4% Adjusted EBITDA 10.1m 12.5m Adjusted EBITDA % 11.4% 18.1% Depreciation & amortisation ( 2.9m) ( 1.6m) Share based payments ( 0.8m) ( 0.1m) Impairments & exceptionals ( 16.2m) ( 3.3m) Operating (loss) profit ( 9.8m) 7.5m Loss on discontinued operations ( 13.7m) ( 0.3m) 12
14 Adjusting items Continuing operations m Composition of 2017 impairments Group adjusted EBITDA 10.1m 12.5m 2.4m Depreciation & amortisation ( 2.9m) ( 1.6m) Simplification - products Impairments ( 10.0m) ( 0.1m) Exceptionals 1 ( 6.2m) ( 3.2m) 7.2m Medication Adherence Other Share-based payments ( 0.8m) ( 0.1m) Group statutory operating (loss) profit ( 9.8m) 7.5m 1.1m 0.4m Composition of 2017 exceptionals 2.0m Lamda deferred consideration 1 Non-recurring and non-operational items Simplification - reorganisation Board changes Other 2.7m 13
15 Adjusted EBITDA Revenue Revenue bridge ( m) MA growth in homecare sector Homecare sector low margin activity Adjusted EBITDA 40.0 FY17 a year of significant change 20.0 Group margin impacted by mix of divisional activity Specials Niche Medication Adherence 2017 Divisional performance: Specials pricing and product mix Niche simplification offsetting new product launches MA entry in new business activity Adjusted EBITDA bridge ( m) Specials Niche Medication Adherence Group costs
16 m Cash flow The Group generated 6.5m of operating cash excluding the impact of non-cash impairments, depreciation and amortisation Group continues to benefit from strong working capital management established in H1 Majority of capital expenditure relates to capitalised development expenditure ( 4.0m) Cash impact of discontinued operation represents substantially all of the expected cash cost of closing NuPharm (5.0) (9.8) (0.9) 0.5 (2.4) (1.3) (2.0) (4.0) (6.0) (8.0) (10.0) (12.0) Operating loss Depreciation/ amortisation/ impairments Share based payments Mvt in working capital Cash generated from continuing operations Capex Interest paid Net tax receipt Discontinued operation Free cash flow 15
17 Net debt Group banking facilities comprise: Net debt ( m) Term loan m outstanding at year end. 10m revolving credit facility ( RCF ) undrawn at the year-end (14.3) Net debt reduced by almost half by 15.0m fundraise ( 14.3m after expenses) completed in November Debt repayments comprised 3m against term loan and 5m to pay down RCF Opening net debt Free cash flow Proceeds from equity fundraise Dividends paid Other Closing net movements debt 16
18 Outlook Chris Rigg, Chief Executive Officer 17
19 Outlook Strong progress in transition to focused and simplified business Line drawn under historical issues reflected in results Secured key routes to market through long-term contracts in the Specials division Simplified portfolio of launched products in Niche division performing well A number of successful launches post year-end and performing to plan Development pipeline progressing to plan with known routes to market Commercial partnerships being progressed Run-rate profitability supportive of market expectations Confident in the future 18
20 Chris Rigg Chief Executive Officer Gerard Murray Chief Financial Officer Quantum Pharma Plc Quantum House, Hobson Industrial Estate Burnopfield, Co. Durham, NE16 6EA 19
21 Appendices 20
22 Divisional Summary Revenue and EBITDA by division Specials ( m) Niche ( m) (5.0) Medication Adherence ( m) (0.2) Revenue Adjusted EBITDA Revenue growth of 7% reflects growth in lower-margin special obtains volumes and aseptic compounding Growth net of tariff pricing impact, Glyco cannibalisation & short-term softness in ULM 1 Gross margin reduction impacted by revenue mix and FX headwinds in H2 Revenue growth driven by new product launches (including Glyco) and increased third-party development activity Revenue headwinds include declining out-licensing income and simplification actions Cost base increased through investment in go-to-market infrastructure in H1 now addressed Significant revenue growth driven by new homecare contract wins Homecare business operates at very low margin Adjusted EBITDA loss reflecting change in business model and investment to support expansion Division exited the year generating positive EBITDA Operational gearing benefits in H2 21
Looking to the medium term
Looking to the medium term Issued: 4 September 2013 Legal notice This presentation has been prepared to inform investors and prospective investors in the secondary markets about the Group and does not
More informationResponsible investment in growth
Responsible investment in growth Issued: 1 March 2016 Legal notice This presentation has been prepared to inform investors and prospective investors in the secondary markets about the Group and does not
More informationFinancial & Business Highlights For the Year Ended June 30, 2017
Financial & Business Highlights For the Year Ended June, 17 17 16 15 14 13 12 Profit and Loss Account Operating Revenue 858 590 648 415 172 174 Investment gains net 5 162 909 825 322 516 Other 262 146
More informationResponsible investment in growth
Responsible investment in growth Issued: 17 June 2014 Legal notice This presentation has been prepared to inform investors and prospective investors in the secondary markets about the Group and does not
More informationHalf Year Results. for the six months ended 30 November January Chairman Chris Stone CEO Adam Palser CFO Brian Tenner
Half Year Results for the six months ended 30 November 2017 16 January 2018 Chairman Chris Stone CEO Adam Palser CFO Brian Tenner Agenda Overview and strategy update Financial highlights Financial performance
More informationTable of Contents. Page 1-3 Page 4-5 Page 6 Page 7 Page 8-10 Page 11
Table of Contents 1. Consolidated Financial Results 2. Growth in Productive Assets 3. Group Return on Assets Analysis 4. Group Profitability Analysis 5. Divisional Performance Indicators 6. Glossary Page
More informationAUGUSTA CAPITAL LIMITED FY2017 ANNUAL RESULT BRIEFING. 30 May 2017
FY2017 ANNUAL RESULT BRIEFING 30 May 2017 FY2017 ANNUAL RESULT BRIEFING Contents 1. HIGHLIGHTS 2. KEY EVENTS 3. ANNUAL RESULTS 4. FUNDS MANAGEMENT 5. LOOKING FORWARD 2 FY2017 ANNUAL RESULT BRIEFING - HIGHLIGHTS
More informationTERMS OF REFERENCE FOR THE INVESTMENT COMMITTEE
I. PURPOSE The purpose of the Investment Committee (the Committee ) is to recommend to the Board the investment policy, including the asset mix policy and the appropriate benchmark for both ICBC and any
More informationHeadlines. Adjusted operating profit (excluding IAS 19 impact) 47.4m +4% 3.0m +16% (excluding IAS 19 impact) 2.8m +17% 2.3m +14% Net borrowings
1 Headlines Revenue (sept 2016: 45.4m) Adjusted operating profit (excluding IAS 19 impact) (sept 2016: 2.6m) 47.4m +4% 3.0m +16% Adjusted profit before tax (excluding IAS 19 impact) (sept 2016: 2.4m) Profit
More informationFor personal use only
FY16 FULL YEAR RESULTS REVIEW Agenda GROUP RESULTS OVERVIEW BUSINESS UNIT REVIEW OUTLOOK Eastlands Shopping Centre BSA completed the mechanical services upgrade and extension to one 29/08/2016 BSA Limited
More informationAgenda. Results Presentation 21 August Appendices 1 to
Results Presentation 21 August 2018 45 Agenda Results Presentation 21 August 2018 Page Highlights 1 Strategy 2 Review of operations 3 Outlook 12 Financial review 14 Summary 26 Appendices 1 to 10 27-43
More informationAgenda. Results Presentation 27 February Appendices 1 to
Results Presentation 27 February 2018 51 Agenda Results Presentation 27 February 2018 Page Presented by Overview 1 Jeff Fairburn Review of operations 3 Jeff Fairburn Outlook 13 Jeff Fairburn Financial
More informationAvailability, Reliability, Ease. 11 September 2018
Availability, Reliability, Ease 11 September 2018 LEGAL NOTICE This presentation has been prepared to inform investors and prospective investors in the secondary markets about the Group and does not constitute
More information2017 Interim Results. 14 September 2017
2017 Interim Results 14 September 2017 1 Disclaimer NOT FOR PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT
More informationThe Property Franchise Group. Half Year Results September 2016
The Property Franchise Group Half Year Results September 2016 Agenda 2 Overview Ian Wilson, Chief Executive Officer Financial performance David Raggett, Chief Financial Officer Operational performance
More informationGrowth and diversification. 7 March 2017
Growth and diversification 7 March 2017 LEGAL NOTICE 2 This presentation has been prepared to inform investors and prospective investors in the secondary markets about the Group and does not constitute
More informationExecutive Summary. July 17, 2015
Executive Summary July 17, 2015 The Revenue Estimating Conference adopted interest rates for use in the state budgeting process. The adopted interest rates take into consideration current benchmark rates
More informationANNOUNCEMENT OF PRELIMINARY RESULTS
The leading high service distributor to engineers worldwide ANNOUNCEMENT OF PRELIMINARY RESULTS YEAR ENDED 31 MARCH 2009 29 May 2009 Agenda Overview and current trading Ian Mason Financial performance
More informationRebalanced ITV delivers continued good growth Interim Results 2016
Rebalanced ITV delivers continued good growth Interim Results 2016 27 July 2016 Agenda Key Messages and H1 Highlights Adam Crozier Half Year Financial Results Ian Griffiths Strategic Outlook Adam Crozier
More informationFoxtons Interim results presentation For the period ended 30 June 2018
Foxtons Interim results presentation For the period ended 30 June 2018 Important information This presentation includes statements that are, or may be deemed to be, forward-looking statements. These forward-looking
More informationSingapore Exchange Limited Building Tomorrow s Market, Today
Singapore Exchange Limited Building Tomorrow s Market, Today Singapore Exchange SGX: Building Tomorrow s Market, Today SGX: Our Fundamentals FY2002 Half Year Results Going Forward SGX: Building Tomorrow
More informationBusiness & Financial Services December 2017
Business & Financial Services December 217 Completed Procurement Transactions by Month 2 4 175 15 125 1 75 5 2 1 Business Days to Complete 25 Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec 217 Procurement
More informationFY17 results presentation. Andrew Rashbass and Colin Jones 22 November 2017
FY17 results presentation Andrew Rashbass and Colin Jones 22 November 2017 Strategic journey Message from our Investor Day in March 2016 2016 no outward change 2017 year of transition 2018 year of growth
More informationXML Publisher Balance Sheet Vision Operations (USA) Feb-02
Page:1 Apr-01 May-01 Jun-01 Jul-01 ASSETS Current Assets Cash and Short Term Investments 15,862,304 51,998,607 9,198,226 Accounts Receivable - Net of Allowance 2,560,786
More informationBig Walnut Local School District
Big Walnut Local School District Monthly Financial Report for the month ended September 30, 2012 Prepared By: Felicia Drummey Treasurer BIG WALNUT LOCAL SCHOOL DISTRICT SUMMARY OF YEAR-TO-DATE FINANCIAL
More informationReview of Registered Charites Compliance Rates with Annual Reporting Requirements 2016
Review of Registered Charites Compliance Rates with Annual Reporting Requirements 2016 October 2017 The Charities Regulator, in accordance with the provisions of section 14 of the Charities Act 2009, carried
More information2017 Half-year results presentation. Andrew Rashbass and Colin Jones 18 May 2017
2017 Half-year results presentation Andrew Rashbass and Colin Jones 18 May 2017 Context Investor Day in March 2016 Flagged 2017 as a year of transition DMGT sell-down an accelerator of the strategy Page
More information37 th Annual JP Morgan Healthcare Conference. January 8, 2019
37 th Annual JP Morgan Healthcare Conference January 8, 2019 Safe Harbor Statement This presentation contains forward-looking statements and information that involve risks, uncertainties and assumptions.
More informationDivision of Bond Finance Interest Rate Calculations. Revenue Estimating Conference Interest Rates Used for Appropriations, including PECO Bond Rates
Division of Bond Finance Interest Rate Calculations Revenue Estimating Conference Interest Rates Used for Appropriations, including PECO Bond Rates November 16, 2018 Division of Bond Finance Calculation
More information1H18 Results Presentation Sid Takla Interim Chief Executive Officer Lyndal York Chief Financial Officer
1H18 Results Presentation Sid Takla Interim Chief Executive Officer Lyndal York Chief Financial Officer 21 August 2018 Important Notice and Disclaimer This presentation has been prepared by Asaleo Care
More informationResults presentation. Highlights. For the year-ended 31 March A distinctive specialist banking group
Results presentation For the year-ended 31 March 26 A distinctive specialist banking group Highlights Constant pursuit of a sustainable, distinctive growth strategy Strong results 25 Investec plc relative
More informationGoldman Sachs 2012 Leveraged Finance Healthcare Conference MATTHEW WALSH SVP FINANCE & CFO
Goldman Sachs 2012 Leveraged Finance Healthcare Conference MATTHEW WALSH SVP FINANCE & CFO 05.01.2012 Forward Looking Statements This presentation contains both historical and forward-looking statements.
More information1.2 The purpose of the Finance Committee is to assist the Board in fulfilling its oversight responsibilities related to:
Category: BOARD PROCESS Title: Terms of Reference for the Finance Committee Reference Number: AB-331 Last Approved: February 22, 2018 Last Reviewed: February 22, 2018 1. PURPOSE 1.1 Primary responsibility
More informationMaking it happen. 6 March 2018
Making it happen 6 March 2018 LEGAL NOTICE This presentation has been prepared to inform investors and prospective investors in the secondary markets about the Group and does not constitute an offer of
More informationParagon Banking Group PLC. Financial Results for twelve months ended 30 September 2018
Paragon Banking Group PLC Financial Results for twelve months ended 3 September 218 218 results highlights 2 Strong financial performance and further strategic progress Strong operational performance New
More informationFoxtons Interim results presentation For the period ended June 2017
Foxtons Interim results presentation For the period ended June 2017 Important information This presentation includes statements that are, or may be deemed to be, forward-looking statements. These forward-looking
More informationPRESS RELEASE. Securities issued by Hungarian residents and breakdown by holding sectors. January 2019
7 March 2019 PRESS RELEASE Securities issued by Hungarian residents and breakdown by holding sectors January 2019 According to securities statistics, the amount outstanding of equity securities and debt
More informationHIPIOWA - IOWA COMPREHENSIVE HEALTH ASSOCIATION Unaudited Balance Sheet As of July 31
Unaudited Balance Sheet As of July 31 Total Enrollment: 407 Assets: Cash $ 9,541,661 $ 1,237,950 Invested Cash 781,689 8,630,624 Premiums Receivable 16,445 299,134 Prepaid 32,930 34,403 Assessments Receivable
More informationHIPIOWA - IOWA COMPREHENSIVE HEALTH ASSOCIATION Unaudited Balance Sheet As of January 31
Unaudited Balance Sheet As of January 31 Total Enrollment: 371 Assets: Cash $ 1,408,868 $ 1,375,117 Invested Cash 4,664,286 4,136,167 Premiums Receivable 94,152 91,261 Prepaid 32,270 33,421 Assessments
More informationResults presentation. For the year ended 31 March 2014
Results presentation For the year ended 31 March 214 The year in review 2 Improving operating environment Results impacted by strength of sterling against other operating currencies Equity markets Interest
More informationInvestor Presentation February 2019
Investor Presentation February 2019 Dr. Reddy s Laboratories Limited Hyderabad, India BSE: 500124 NSE: DRREDDY NYSE: RDY Safe Harbor Statement This presentation contains forward-looking statements and
More informationQ Earnings Summary August 5, 2015
Q2 2015 Earnings Summary August 5, 2015 Trademark of Trinseo S.A. or its affiliates Introductions & Disclosure Rules Introductions Chris Pappas, President & CEO John Feenan, Executive Vice President &
More information(Registration no C) (Registration no C) Financial Results. (unaudited) 11 November 2009
3 rd Quarter and 9-Month 9 2009 Financial Results (unaudited) 11 November 2009 1 Important note on forward looking statements The presentation herein may contain forward looking statements by the management
More informationResults for the year ended 31 December Capita plc 23 April 2018
Results for the year ended 31 December 2017 Capita plc 23 April 2018 Financial results 2 FY 2017 financial results Underlying income statement m 12 months to 31 December 2017* m 12 months to 31 December
More informationOVERVIEW 1H17 RESULTS
CLICK 1H 2017 TO EDIT RESULTS MASTER TITLE 6 MONTHS ENDED 31 STYLE DECEMBER 2016 OVERVIEW 2 FINANCIAL SUMMARY Group Underlying Reported 1H 2017 1H 2016 1H 2017 1H 2016 Revenue 808.7 794.3 808.7 814.1 EBIT
More informationAvailability, Reliability, Ease. 11 December 2018
Availability, Reliability, Ease 11 December 2018 LEGAL NOTICE This presentation has been prepared to inform investors and prospective investors in the secondary markets about the Group and does not constitute
More informationFINANCIAL RESULTS AND COMPANY OVERVIEW Second-Quarter Performance
FINANCIAL RESULTS AND COMPANY OVERVIEW 08 Second-Quarter Performance September 5 th, 08 Disclaimer Forward-Looking Statements and Preliminary Results This presentation includes forward-looking statements
More information2012 Full Year Results. 27 February 2013
2012 Full Year Results 27 February 2013 Introduction Stephen Harris Chief Executive Induction hardening Used to obtain a hard case for wear resistance or to increase fatigue strength. The induction process
More informationSpheria Australian Smaller Companies Fund
29-Jun-18 $ 2.7686 $ 2.7603 $ 2.7520 28-Jun-18 $ 2.7764 $ 2.7681 $ 2.7598 27-Jun-18 $ 2.7804 $ 2.7721 $ 2.7638 26-Jun-18 $ 2.7857 $ 2.7774 $ 2.7690 25-Jun-18 $ 2.7931 $ 2.7848 $ 2.7764 22-Jun-18 $ 2.7771
More informationITV on track to deliver Interim Results 2017
ITV on track to deliver Interim Results 2017 26 July 2017 Agenda Key Messages and H1 Highlights Peter Bazalgette Half Year Financial and Operating review Ian Griffiths Q&A 2 Key Messages and H1 Highlights
More informationFINANCIAL MANAGEMENT STRATEGY REPORT ON OUTCOMES FOR THE YEAR ENDED MARCH 31, 2016
FINANCIAL MANAGEMENT STRATEGY REPORT ON OUTCOMES FOR THE YEAR ENDED MARCH 31, 2016 Manitoba Finance General Inquiries: Room 109, Legislative Building Winnipeg, Manitoba R3C 0V8 Phone: 204-945-5343 Fax:
More informationAgenda. Results Presentation 27 February Appendices 1 to
Results Presentation 27 February 2017 55 Agenda Results Presentation 27 February 2017 Page Presented by Chairman s overview 1 Nicholas Wrigley Review of operations 3 Jeff Fairburn Outlook 13 Jeff Fairburn
More informationAgenda Item 7 Date: 30 November Rob Forster, Director of Finance & IM&T. Approve Adopt Receive for information
Trust Board Agenda Item 7 Date: 30 November 20 Title of Report Finance Board Report Month 7 Purpose of the report and the key issues for consideration/decision To update Trust Board on the monthly financial
More informationBig Walnut Local School District
Big Walnut Local School District Monthly Financial Report for the month ended September 30, 2013 Prepared By: Felicia Drummey Treasurer BIG WALNUT LOCAL SCHOOL DISTRICT SUMMARY OF YEAR TO DATE FINANCIAL
More informationPreliminary Results. 22nd February 2018
Preliminary Results 22nd February 2018 Mark Lewis Chief Executive Officer Matthew Price Chief Financial Officer Full year themes Diversified business delivering stable returns Doing a great job for our
More informationResults for the year ended 31 December February 2016 Capita plc
Results for the year ended 31 December 2015 25 February 2016 Capita plc 1 Agenda Strategy and key highlights Andy Parker, Chief Executive Financial results Nick Greatorex, Group Finance Director Business
More informationIntegrated Dental Holdings. Q4 FY2018 and year-end results - investor presentation 27 June 2018
Integrated Dental Holdings Q4 FY2018 and year-end results - investor presentation 27 June 2018 DISCLAIMER THIS PRESENTATION IS NOT AN OFFER OR SOLICITATION OF AN OFFER TO BUY OR SELL SECURITIES IN THE
More informationHUD NSP-1 Reporting Apr 2010 Grantee Report - New Mexico State Program
HUD NSP-1 Reporting Apr 2010 Grantee Report - State Program State Program NSP-1 Grant Amount is $19,600,000 $9,355,381 (47.7%) has been committed $4,010,874 (20.5%) has been expended Grant Number HUD Region
More informationACQUISITION OF CSM ACQUISITION OF IQONE
FULL YEAR RESULTS Year ended 30 June 2018 ACQUISITION OF CSM ACQUISITION OF IQONE 27 September 2018 CAUTIONARY STATEMENT This presentation contains certain statements that are neither reported financial
More informationCambridge Industrial Trust. 29 Jan 2008
Cambridge Industrial Trust Full Year 2007 Results 29 Jan 2008 FY2007 Results Presentation Outline FY 2007 Milestones 4Q2007 Financial Results Capital Management Strategy Acquisition Highlights Portfolio
More informationPerformance Report October 2018
Structured Investments Indicative Report October 2018 This report illustrates the indicative performance of all Structured Investment Strategies from inception to 31 October 2018 Matured Investment Strategies
More informationKerry Interim Results Presentation
Kerry - 2005 Interim Results Presentation Introduction and Overview Hugh Friel Financial Review Brian Mehigan Business Review Hugh Friel Prospects and Future Development Hugh Friel Q&A H1 2005: Solid Performance
More informationAutogrill Group - 3Q2008 YTD Results. 6 November 2008
Autogrill Group - 3Q2008 YTD Results 6 November 2008 FORWARD LOOKING STATEMENTS This presentation is of a purely informative nature and does not constitute an offer to sell, exchange or buy securities
More informationFrank Fiskers, President & CEO Gunilla Rudebjer, CFO Stockholm, May 12, 2016
Frank Fiskers, President & CEO Gunilla Rudebjer, CFO Stockholm, May 12, 1 Strong business momentum with continued healthy underlying demand Norway - still a mixed picture but some stabilisation Ongoing
More informationNKT Holding. Interim Report Q Audiocast presentation 8 November 2012 at 10:00 am CET
NKT Holding Interim Report Q3 2012 Audiocast presentation 8 November 2012 at 10:00 am CET Agenda Page Page 2 2 NKT Group Highlights Q3 2012 Financial results Q3 2012 Companies NKT Cables Nilfisk-Advance
More informationTHE B E A CH TO WN S O F P ALM B EA CH
THE B E A CH TO WN S O F P ALM B EA CH C OU N T Y F LO R I D A August www.luxuryhomemarketing.com PALM BEACH TOWNS SINGLE-FAMILY HOMES LUXURY INVENTORY VS. SALES JULY Sales Luxury Benchmark Price : 7,
More informationCharles Mickey Flood. Joe Quarin. Investor Presentation May Executive Vice President, BFI Canada, CEO IESI. Chief Financial Officer BFI Canada
Charles Mickey Flood Executive Vice President, BFI Canada, CEO IESI Joe Quarin Chief Financial Officer BFI Canada Investor Presentation May 2005 Safe Harbor Statement Our remarks and answers to your questions
More informationTHIRD QUARTER FISCAL YEAR 2018 Earnings Conference Call & Presentation. August 7, 2018 at 9:00 a.m. CT (10:00 a.m. ET)
THIRD QUARTER FISCAL YEAR 2018 Earnings Conference Call & Presentation August 7, 2018 at 9:00 a.m. CT (10:00 a.m. ET) 1 Third Quarter Fiscal Year 2018 Welcome to Nexeo s Earnings Conference Call and Presentation
More informationQ4 AND FULL YEAR 2017 UPDATE. March 1, 2018
Q4 AND FULL YEAR 2017 UPDATE March 1, 2018 SAFE HARBOR STATEMENT This presentation and any statements made for and during any presentation or meeting contain forward-looking statements related to Synergy
More informationMaking it happen. 13 June 2017
Making it happen 13 June 2017 LEGAL NOTICE This presentation has been prepared to inform investors and prospective investors in the secondary markets about the Group and does not constitute an offer of
More informationFY 2015 Results Presentation. 19 January 2016
FY 2015 Results Presentation 19 January 2016 Disclaimer THIS PRESENTATION IS NOT AN OFFER OR SOLICITATION OF AN OFFER TO BUY OR SELL SECURITIES IN THE UNITED STATES OF AMERICA OR IN ANY OTHER JURISDICTION.
More information11 May Report.xls Office of Budget & Fiscal Planning
Education and General Fund Actual Revenues and s by Month MTD YTD Change Revenue Jul Aug Sep Oct Nov Dec Jan Feb Mar Apr May Jun Per 14 Total over FY06 Enrollment Fees $ 8,211 $ 219 $ 41,952 ($ 818) $
More informationBank of Queensland Full year results 31 August Bank of Queensland Limited ABN AFSL No
Bank of Queensland Full year results 31 August 2013 Bank of Queensland Limited ABN 32 009 656 740. AFSL No 244616. Agenda Result overview Stuart Grimshaw Managing Director and CEO Financial detail Anthony
More informationPaddy Power Betfair plc Prelim Results
Paddy Power Betfair plc 2016 Prelim Results Financial & Operating Review [find new imagery for cover] Financial highlights 3 m, Proforma 1 2016 2015 YOY % YOY % CC 2 Revenue 1,551 1,318 +18% +11% Cost
More informationRaymond James 37 th Annual Institutional Investors Conference. March 8, 2016
Raymond James 37 th Annual Institutional Investors Conference March 8, 2016 Forward-looking statements and Non-GAAP financial measures Forward-looking statements Certain statements included in this presentation,
More informationBusiness Update. USPP Conference Miami. Luis Damasceno Group CFO Michael Williams Group Finance Director & Treasurer January 2019
Business Update USPP Conference Miami Luis Damasceno Group CFO Michael Williams Group Finance Director & Treasurer 23-25 January 2019 www.alsglobal.com IMPORTANT NOTICE AND DISCLAIMER This presentation
More informationAegis Group plc Half Year Results. 27 August 2010
Aegis Group plc 2010 Half Year Results 27 August 2010 Agenda Introduction John Napier, Chairman Aegis Group overview Jerry Buhlmann, CEO Divisional review Aegis Media - Jerry Buhlmann, CEO Synovate Robert
More informationSecond Quarter 2018 Financial Results
August 2, 2018 Second Quarter 2018 Financial Results Trademark of Trinseo S.A. or its affiliates Trademark of Trinseo S.A. or its affiliates 1 Introductions & Disclosure Rules Introductions Chris Pappas,
More informationDecember 31, OVERVIEW 2 MAGELLAN 2017 ANNUAL REPORT
1. OVERVIEW 2 MAGELLAN 2017 ANNUAL REPORT 2017 and Recent Updates MAGELLAN 2017 ANNUAL REPORT 3 Labour Matters 4 MAGELLAN 2017 ANNUAL REPORT Financing Matters 2. OUTLOOK MAGELLAN 2017 ANNUAL REPORT 5 TM
More informationResults Presentation Half year ended 31 March Thursday 25 May 2017
Results Presentation Half year ended 31 March 2017 Thursday 25 May 2017 Agenda 1. Highlights Paul Zwillenberg, CEO 2. Financial Performance Tim Collier, CFO 3. Strategy and Business Update Paul Zwillenberg,
More informationAUDITED RESULTS FOR THE YEAR ENDED 31 DECEMBER 2016
AUDITED RESULTS FOR THE YEAR ENDED 31 DECEMBER 2016 AGENDA 2 1 Opening remarks / market update 2 Financial results 3 Operational review 4 Strategy update 5 Outlook 1 2 3 4 5 OPENING REMARKS / MARKET UPDATE
More informationFor personal use only
Market Office Announcement ASX Limited Date: 9 November 2018 THINK CHILDCARE LIMITED ( TNK ) ACQUIRES 5 CHILDCARE CENTRES AND REDUCES YEAR ON YEAR OCCUPANCY GAP TO 0.5% TNK has contracted to acquire five
More informationKingston Hospital NHS Foundation Trust. Finance Report December 2017 (Month 09)
Original 0 0 0 ' s Kingston Hospital NHS Foundation Trust Finance Report December 2017 (Month 09) CONTENTS EXECUTIVE SUMMARY........3 SECTION 1: OVERALL INCOME AND EXPENDITURE.......4 SECTION 2: DIVISIONAL
More informationTeva Pharmaceutical Industries Ltd. Q August 2, 2018
Teva Pharmaceutical Industries Ltd. Q2 2018 August 2, 2018 Cautionary Note Regarding Forward-Looking Statements 2 This presentation contains forward-looking statements within the meaning of the Private
More informationRESULTS PRESENTATION. For the fiscal half year ended September 30, November 12, 2018
RESULTS PRESENTATION For the fiscal half year ended September 30, 2018 November 12, 2018 DISCLAIMER This presentation contains "forward-looking statements relating to VivoPower International PLC ( VivoPower
More informationFourth quarter results 2015
1 Fourth quarter results 2015 11 February 2016 Peter A. Ruzicka, President & CEO Continued growth in the fourth quarter 4.1% organic growth 1 17% EBIT (adj.) 2 growth in BCG Full-year EPS doubled to NOK
More informationH1 16 interim results. 22 September 2015
H1 16 interim results 22 September 2015 Important notice 2 This presentation may include certain forward-looking statements, beliefs or opinions, including statements with respect to the Company s business,
More informationFY2015 Annual Results August Brett McKeon - CEO David Bailey - CFO
FY2015 Annual Results August 27 2015 Brett McKeon - CEO David Bailey - CFO FY2015 Financial Results Highlights Delivery on FY15 Prospectus forecasts Pro forma NPAT $19.3 million up 8.4% against IPO forecast
More informationFoxtons Preliminary results presentation For the year ended December 2018
Foxtons Preliminary results presentation For the year ended December 2018 Important information This presentation includes statements that are, or may be deemed to be, forward-looking statements. These
More informationFY4/18 2Q IR PRESENTATION
IR PRESENTATION December 2017 2Q Results Overview 1 Consolidated P/L Net sales increased 13.3% year on year and 2.3% against the plan due to firm growth in same stores and stores that were opened in previous
More informationResults Presentation. For the year ended
Results Presentation For the year ended 31 3 213 1 The year in review 2 Mixed operating environment Strong equity markets but a weak Rand Equity markets Interest rates 13 12 11 1 9 +18.8% +12.7% +12.6%
More informationEarnings Call. December 19, 2017
Earnings Call December 19, Safe Harbor This document contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including forward-looking
More information27 July 2018 Interim Results
27 July 2018 Interim Results for the half year ended 30 June 2018 Disclaimer This presentation may contain forward-looking statements, including forward-looking statements within the meaning of the United
More information2016 Full Year Results Presentation 14 February 2017
2016 Full Year Results Presentation 14 February 2017 Contents Overview of 2016 results 2016 financial and operational performance Outlook for 2017 Dividend Further information This full year results presentation
More informationFoundations of Investing
www.edwardjones.com Member SIPC Foundations of Investing 1 5 HOW CAN I STAY ON TRACK? 4 HOW DO I GET THERE? 1 WHERE AM I TODAY? MY FINANCIAL NEEDS 3 CAN I GET THERE? 2 WHERE WOULD I LIKE TO BE? 2 Develop
More informationDomino s Pizza UK & IRL plc. Interim Results for the 26 weeks ended 28 June 2009
Domino s Pizza UK & IRL plc Interim Results for the 26 weeks ended 28 June 2009 m System sales momentum 210 System sales have doubled since 2005 196.4 190 170.2 170 150 130 110 97.1 114.8 142.5 +24.1%
More informationCembrit Group Q Unaudited interim report
Cembrit Group Q4 2017 Unaudited interim report 2017 main events COMMENTARY Strong demand across both markets and product categories resulted in revenue growth of 7.9% YoY 2017 EBITDA showed solid underlying
More informationOTHER DEPOSITS FINANCIAL INSTITUTIONS DEPOSIT BARKAT SAVING ACCOUNT
WEIGHTAGES JAN FEB MAR APR MAY JUN JUL AUG SEPT OCT NOV DEC ANNOUNCEMENT DATE 19.Dez.14 27.Jän.15 24.Feb.15 26.Mär.15 27.Apr.15 26.Mai.15 25.Jun.15 28.Jul.15 26.Aug.15 23.Sep.15 27.Okt.15 25.Nov.15 MUDARIB
More informationUDG Healthcare plc Interim Results Presentation FY17. London Stock Exchange, 23 rd May 2017
UDG Healthcare plc Interim Results Presentation FY17 London Stock Exchange, 23 rd May 2017 Forward looking statements This Presentation has been prepared by UDG Healthcare plc and contains certain forward-looking
More information2011 Interim Results. Keith Gordon, Managing Director & Chief Executive Officer Stephen Gobby, Chief Financial Officer
2011 Interim Results Keith Gordon, Managing Director & Chief Executive Officer Stephen Gobby, Chief Financial Officer Emeco 2011 Interim Results Overview Financials Strategy & Outlook Questions Appendices
More information